TCR Modulator Market: Competitive Landscape, Pipeline, and Market Analysis 2024

TCR is a group of proteins found in T cells (a type of immune cell that recognizes and binds to foreign substances). TCRs bind to certain antigens (proteins) found on abnormal cells, cancer cells, cells from other organisms, and cells infected with a virus or another microorganism. This interaction causes the T cells to attack these cells and helps the body fight infection, cancer, or other diseases. Also called a T-cell receptor. and the molecules that activate T-cell receptors are called TCR modulators. TCR Modulators are used to treat carcinoma, sarcoma, bronchial neoplasms, immunoproliferative disorders, lymphoma, blood coagulation disorders, digestive system disorders, endocrine system diseases, gastrointestinal disorders, hematologic diseases, multiple myeloma, respiratory tract diseases, thoracic neoplasm, vaginal cancer, etc. Increased prevalence of immunoproliferative diseases, government reimbursement policies, and increased investment in R&D are the key drivers for the TCR modulators. For instance, according to the International Agency for Research on Cancer 2020, the Estimated number of new cases of multiple myeloma and immunoproliferative diseases from 2020 to 2040 for all ages will be 1,06,245 in Asia, 64,143 in Europe, 48,929 in North America, 26,017 in Latin America and the Caribbean, 16,709 in Africa and 4,813 in Oceania market. Moreover, the Launch of newer products by the market players significantly enhances the revenue of the TCR Modulators market over the forecast years. For instance, Salix Pharmaceuticals cycloset (bromocriptine mesylate) for the treatment of type 2 diabetes mellitus. Sunovion Pharmaceuticals Kynmobi (Apomorphine Hydrochloride) for treatment of Parkinson's disease. The development of other molecules by many market players is coming up with more treatment options. For instance, Newron’s Sarizotan (EMD128130) for the antipsychotic effect, and UCB’s Rotigotine Intranasal (SPM 952) for Parkinson disease are under the various stages of clinical studies.

Key Market Developments:

• In March 2021, FDA approved Kite Pharmaceuticals Yescarta (Axicabtagene Ciloleucel) for the new indication of adult patients with relapsed or refractory follicular lymphoma.
• In May 2023, FDA approved Abbvie’s Epkinly (Epcoritamab) first and only bispecific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Approved Drug Molecules with the Brand Names:

 Epkinly (Epcoritamab-Bysp)

Yescarta (Axicabtagene Ciloleucel)

Kymriah (Tisagenlecleucel)

Drugs under the Pipeline:

Utomilumab (PF-05082566)

Letetresgene Autoleucel (GSK3377794)

Ny-Eso-1 Tcr

Liocyx-M

Taest16001

Afamitresgene Autoleucel (ADP-A2M4)

Mipetresgene Autoleucel (TBI-1301)

Adp-A2m10

Cytorex EBV (Baltaleucel-T)

Kite-718

KK-LC-1 TCR Therapy

Ksh01

Mage A3 Tcr

Library TCR-T-Cell Therapy

Adp-A2afp

Crte7a2-01

E6 Tcr

Fit-001

Hbi 0201-Eso Tcrt

Hryz-T101

Ima101

Ima201

Ima203cd8

Ima401

Imc-C103c

Kind T

Ksx01

Lyl132

Liocyx

Nt-175

NY-ESO-1 TCR-T Cell Therapy

Neotcr-P1

Sar444200

T-Cell Receptor Therapy

Tbi 1201

Tc-N201

Tsc-100

Tsc-101

Clinical Activity and Developments of TCR Modulator Molecules:

As of June 2023, more than 20 companies have approximately 23 molecules for the above 30 diseases. For these molecules, more than 40 clinical trials are being conducted by players across the globe. For instance,

• In April 2023, Novartis AG completed phase 2, single-arm, multicenter open-label trial

 to determine the safety and efficacy of Tisagenlecleucel in pediatrics with relapsed or

 refractory mature B-cell Non-Hodgkin lymphoma.

• In June 2023, Pfizer conducted a phase 1 study of Avelumab plus Utomilumab combination therapy for refractory large B-cell lymphoma and mantle cell lymphoma.